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Introduction
Tumours causing distal malignant biliary obstruction may 
arise in the head of the pancreas, duodenum, ampulla or distal 
common bile duct. Pancreatic cancers account for about two 
thirds of these cases, followed by ampullary cancers (about 
20%) and distal cholangiocarcinomas (15%). Eighty percent of 
patients who present with distal malignant biliary obstruction 
are not candidates for surgical resection and require palliative 
treatment.1 Endoscopic biliary stenting has become the 
preferred method for relieving obstructive jaundice in these 
patients.2 There have been significant advances in stent 
technology since the first plastic endoscopic biliary stent was 
placed in 1979.3 A major improvement was the development 
of self-expanding metal stents (SEMS). Initially SEMS were 
uncovered but there are now also commercially available 
fully covered and partially covered SEMS. There have been 
a number of studies comparing plastic stents to SEMS, but no 
such studies have been performed in an African institution.4-9 
The studies that have been conducted have consistently 
shown that plastic stents have a higher occlusion rate and 
shorter patency compared to SEMS. Plastic stents do have 
some advantages over SEMS. They are cheaper and are 
easily removable, as opposed to in particular non-covered 
SEMS. The aim of this study was to determine the safety and 
clinical effectiveness of 10Fr plastic biliary stents compared 
to uncovered SEMS for palliative treatment of patients with 
inoperable but non-metastasized periampullary malignant 
biliary obstruction in a public hospital in South Africa.
Patients and methods
Between January 2009 and December 2013, eligble patients 
with symptomatic jaundice due to irresectable periampullary 
cancer were randomised to either a 10Fr plastic stent or an 
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uncovered SEMS. The inclusion and exclusion criteria are 
shown in Table 1. Randomisation was on a 1:1 basis, using 
computer generated numbers placed in opaque envelopes. 
Patients were randomised once a guidewire had successfully 
been positioned across the stricture during endoscopic 
retrograde cholangiopancreatography (ERCP). A standard 
polyethylene plastic stent (Boston Scientific, MA, USA) 
with proximal and distal flanges or an uncovered SEMS 
(Boston Scientific, MA, USA) with 10 mm diameter were 
used. A plastic stent cost R 1437.86 and a metal stent cost 
R 6 422.28 (prices in 2013). The lengths of the stents were 
chosen according to the extent of the stricture. Adhering to the 
CONSORT criteria, all patients presenting with periampullary 
carcinoma were entered in a database. Patients were evaluated 
with US, CT and/or MRI and reviewed at a MDT meeting to 
assess resectability.
Table 1. Inclusion and exclusion criteria
Inclusion Criteria Exclusion Criteria
Clinical data suggestive of 
a distal malignant bile duct 
obstruction.
18 years of age or older
Information given and informed 
consent obtained 
Bilirubin > 50 umol/L (normal 
26 umol/L) 
Typical radiological appearance 
of malignant common bile duct 
stenosis at ERCP
Proximal margin of malignant 
bile duct stenosis > 2 cm from 
the hepatic confluence 
ECOG* performance status 0-2
Metastatic disease
Resectable patients
Previous gastric surgery 
or duodenal obstruction 
preventing ERCP
Previous inclusion in the study 
Participation in another clinical 
trial in the preceding 90 days
*ECOG Eastern Cooperative Oncology Group
Demographic and clinical data, post-procedural duration 
of hospital stay, complications and need for any additional 
interventions were documented. Patients were followed up 
monthly until the time of death or up to 12 months. At follow-
up liver function tests were performed in patients with a 
clinical suspicion of stent dysfunction. Re-interventions were 
documented. For patients with stent dysfunction the salvage 
strategy was left to the treating endoscopist. Any hospital 
readmissions were recorded, specifying the indication for 
admission.
The primary endpoint in the study was effective palliation 
of biliary obstruction, defined as a functioning stent at time of 
death or at 12 months.
Secondary endpoints included ability to safely deploy the 
stent in a satisfactory position, procedure-related adverse 
events and the need for re-intervention. Ethical approval for 
the trial and the registries from which data was extracted were 
obtained from the University of Cape Town Human Research 
Ethics Committee.
Statistical analysis
Descriptive statistics as appropriate were used to present 
clinical and treatment characteristics and outcome of the study 
subjects. The Fisher exact test and Student’s t-test (unpaired) 
were used to assess differences between the two groups. The 
Kaplan-Meier method was used to estimate survival time 
and probabilities for survival and stent patency times. The 
censored events for stent patency were loss to follow-up, 
death, or patency after 1 year of follow-up. Censored events 
for survival were lost to follow-up. Differences in survival and 
stent patency probabilities were calculated with the log-rank 
test using Stata (version 13.1; Stata Corp, College Station, 
Texas, USA). A p<0.05 was considered statistically significant 
where appropriate.
Table 2. Patient demographic and clinical characteristics at inclusion
Plastic Stent SEMS p-value
No of Patients  n (%) 19 (47.5%) 21 (52.5%)
Males/Females 8/11 9/12 p = 0.61
Median Age  (IQR)* 65 (60–80) 69.5 (59.5–74) p = 0.68
Performance status(ECOG)                0 
                                               1
2
3
4
5
0
4 (21.1%)
15 (78.9%)
0
0
0
1 (4.8%)
5 (23.8%)
15 (71.4%)
0
0
0
p = 0.520
p = 0.569
p = 0.4291
Pancreatic cancer
Cholangiocarcinoma
17
2
18
3
p = 0.5494
Median tumour size cm (range) 3.0 (1.0–4.9) 3.0 (2.0–6.8) p = 0.55
Median Bilirubin umol/l  (range) 338 (71–651) 357 (40–681) p = 0.66
Median Ca-19.9 U/ml (range) 392 (1– > 1000) 256 (16– > 1 000) p = 0.43
*IQR Interquartile range
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Results
A CONSORT flow diagram illustrating the inclusion of 
patients is shown in Figure 1. Forty patients were randomised. 
The demographic and clinical characteristics of the patients 
are summarised in Table 2 which showed no significant 
differences between groups. The intention to treat cohort 
included 17 men and 23 women, with a median age of 
68 years (range 50–85). Thirty-six patients had pancreatic 
cancer and 4 had distal cholangiocarcinoma. 
Follow-up
Patients were followed up until death or for 12 months. In 
the plastic stent group one patient was lost to follow-up after 
three months and another withdrew consent. These patients 
were included in the final intention to treat analysis.
Survival
Median survival in the two groups was similar as assessed 
by the Kaplan-Meier method and the log-rank test (p = 0.18) 
(Figure 2). Thirty four patients (85%) died during the study 
period, 15 in the plastic stent group and 19 in the SEMS 
group. The median survival in the SEMS group was 114 days 
compared to 107 days in the plastic stent group.
Stent patency
There was a significant difference in stent patency (p = 0.043) 
with one of the SEMS (4.7%) and seven of the plastic stents 
(38.8%) occluding during the study period. The patient with 
the blocked SEMS had a stone above the malignant stricture 
that impacted in the stent 3 days after placement. The 
difference in stent patency became significant after six months 
(Table 3, Figure 3). The plastic stents had 25% failure at 
60 days and 50% failure at 351 days.
CONSORT Flow Diagram
Assessed for eligibility (n=427)
Randomized (n= 40)
Excluded  (n= 387)
• Not meeting inclusion criteria  
(n= 293)
• Declined to participate (n= 7)
• Considered resectable (n= 87)
 ◦ Pancreaticoduodenctomy (n=69)
 ◦ Surgical bypass (n=18)
Allocated to Plastic stent (n= 19)
• Received Plastic stent (n= 19)
Lost to follow-up  (n= 1)
Discontinued intervention (n= 1)
Analysed  (n=  19)
• Excluded from analysis (n= 0)
Allocated to Metal  stent (n= 21)
• Received Metal  stent (n= 21)
Lost to follow-up  (n= 0)
Discontinued intervention  (n= 0)
Analysed  (n= 21)
• Excluded from analysis (n= 0)
Enrollment
Allocation
Follow-Up
Analysis
Figure 1
Figure 2. Kaplan Meier Graph comparing survival in the two 
groups
Figure 2 Kaplan Meier Graph comparing survival in the two groups
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Table 3. Survival and stent patency in both groups
Plastic Metal p value
Discharge from 
hospital
(blocked/alive)
0/19 1/21 1.0
At 1 month
(blocked/alive)
2/15 1/20 0.65
At 3 months  
(blocked/alive)
3/11 1/11 0.3306
At 6 months 
(blocked/alive)
6/7 1/7 0.0395
At 9 months 
(blocked/alive)
6/5 1/3 0.0395
At 12 months 
(blocked/alive)
7/4 1/2 0.0174
Stent deployment and complications 
All patients had successful stent deployment and there were 
no ERCP-related complications. There were no unanticipated 
adverse device effects, and no deaths were attributed to the 
investigational device. In two patients (one in each group) 
jaundice did not subside despite patent stents. The cause of 
the prolonged cholestasis could not be ascertained. Four of 
the seven patients with blocked plastic stents presented with 
cholangitis. One patient in each group developed gastric 
outlet obstruction. They were both treated with an uncovered 
duodenal SEMS. One patient in the SEMS group was 
admitted with a bleeding gastric ulcer. Seven patients in the 
plastic stent group spent a total of 44 days in hospital with 
stent related complications compared to one patient in the 
SEMS group who was hospitalised for 21 days. None of the 
patients developed cholecystitis or pancreatitis.
Discussion
This is the first randomised control trial from an African 
institution that compares uncovered SEMS with traditional 
plastic stents for the endoscopic palliation of jaundice in 
patients with periampullary tumours. The findings in the 
study were in keeping with previously reported results, 
comparing uncovered SEMS and plastic stents, showing a 
lower incidence of stent dysfunction and longer stent patency 
in the SEMS groups.4-9 However, the improvement in stent 
patency comes at a considerable expense, with SEMS being 
up to 10 times more expensive than plastic stents. These costs 
are offset by the increased need for re-intervention in patients 
with stent dysfunction.10,11 In this study the difference became 
significant after six months of follow-up. Although the study 
did not address the cost effectiveness of SEMS it has been 
shown that SEMS are more cost effective in patients with a 
longer projected survival.10Follow-up of patients in our patient 
population can be challenging. In spite of this, only one 
patient was lost to follow-up. In our healthcare environment, 
some patients who reside in rural areas have poor access to 
health facilities. These patients often experience considerable 
delays in getting appropriate treatment when they develop 
stent dysfunction. Increased use of SEMS in these patients is 
particularly useful.
There have been a number of randomised control trials 
comparing different types of SEMS (covered, partially 
covered, uncovered) and one randomised control trial 
comparing covered SEMS and plastic stents. Although the 
reason for stent failure differs with the different types of 
SEMS (ingrowth in uncovered SEMS vs. migration in covered 
SEMS), patency rates are similar.12-18As the intention of the 
trial was to test the stents in patients with a life expectancy 
over six months only patients without metastatic disease and 
a good performance status (ECOG 0-2) were included. The 
strict inclusion criteria resulted in a long enrolment period and 
was the main reason for the small number of patients included 
in the study.
None of the patients in this study had a tissue diagnosis 
or received palliative chemotherapy. The diagnosis of 
malignancy was based on the clinical presentation and cross 
sectional imaging. With improved access to endoscopic 
ultrasound we now more frequently attempt to get a tissue 
diagnosis and a greater proportion of patients are receiving 
palliative chemotherapy.
Multiple plastic stents are frequently used to treat patients 
with benign strictures and have been shown to have better 
patency rates than single plastic stents. It has been suggested 
that multiple plastic stents may have a stent patency similar 
to SEMS in malignant strictures.19 There has not been a 
randomised trial comparing multiple plastic stents to SEMS. 
Two or three plastic stents are still considerably cheaper than 
a SEMS. 
In order to ensure that SEMS are used in the most cost 
effective manner, further investigation is required to determine 
which patients are least likely to benefit from SEMS. Novel 
stenting strategies such as the use of multiple plastic stents in 
malignant strictures also need to be studied.
Figure 3. Kaplan Meier Graph comparing stent patency in the 
two groups
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